Xeris Biopharma Holdings Inc. (NASDAQ: XERS) kicked off on May 23, 2023, at the price of $2.94, down -5.42% from the previous trading day. During the day, the shares moved up to $2.94 and dropped to $2.77 before settling in for the closing price of $2.95. Over the past 52 weeks, XERS has traded in a range of $0.97-$3.03.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 134.50%. While this was happening, its average annual earnings per share was recorded 55.10%. With a float of $132.35 million, this company’s outstanding shares have now reached $137.14 million.
Considering the fact that the conglomerate employs 355 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is +69.63, operating margin of -72.97, and the pretax margin is -87.15.
Xeris Biopharma Holdings Inc. (XERS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Xeris Biopharma Holdings Inc. is 2.71%, while institutional ownership is 45.50%. The most recent insider transaction that took place on Dec 13, was worth 29,000. In this transaction the insider of this company bought 20,000 shares at a rate of $1.45, taking the stock ownership to the 1,528,064 shares.
Xeris Biopharma Holdings Inc. (XERS) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 3/30/2023, the organization reported -$0.12 earnings per share (EPS), higher than consensus estimate (set at -$0.17) by $0.05. This company achieved a net margin of -85.86 while generating a return on equity of -134.83. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 55.10% per share during the next fiscal year.
Xeris Biopharma Holdings Inc. (NASDAQ: XERS) Trading Performance Indicators
Take a look at Xeris Biopharma Holdings Inc.’s (XERS) current performance indicators. Last quarter, stock had a quick ratio of 1.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc. (XERS)
Compared to the last year’s volume of 1.27 million, its volume of 0.96 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 61.03%. Additionally, its Average True Range was 0.16.
During the past 100 days, Xeris Biopharma Holdings Inc.’s (XERS) raw stochastic average was set at 88.40%, which indicates a significant increase from 71.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.53% in the past 14 days, which was lower than the 82.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.10, while its 200-day Moving Average is $1.60. Nevertheless, the first resistance level for the watch stands at $2.90 in the near term. At $3.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.07. If the price goes on to break the first support level at $2.73, it is likely to go to the next support level at $2.66. Should the price break the second support level, the third support level stands at $2.56.
Xeris Biopharma Holdings Inc. (NASDAQ: XERS) Key Stats
The company with the Market Capitalisation of 371.15 million has total of 135,531K Shares Outstanding. Its annual sales at the moment are 110,250 K in contrast with the sum of -94,660 K annual income. Company’s last quarter sales were recorded 33,200 K and last quarter income was -16,830 K.
